RECRUITING • Phase NA • Stage III, IV • HER2 negative • Post-Menopausal • Non-interventional

The following is imported from ClinicalTrials.gov:

ACT-MBC: a Study of Circulating Tumor Cells (CTCs) in Metastatic Breast Cancer (MBC)

Brief Summary

ACT-MBC prospectively assesses the impact of CTCs on treatment decisions, response assessment and prognosis in MBC patients.

Description

Study Design

Eligibility Criteria

Arms and Intervention

• CellSearch Circulating Tumor Cells

Inclusion criteria

• 1. invasive breast cancer with radiographic and/or clinical evidence of advanced metastatic or unresectable disease

• 2. er+/her2- patients prior to starting 2nd line therapy or beyond or er/progesterone receptor (pr)/her2-negative (triple negative) patients prior to starting any line of therapy

• 3. measurable and/or non-measurable disease is allowed

• 4. male or female breast cancer is allowed

• 5. age \> 18 years

• 6. willingness to provide mandatory blood specimens

• 7. willing to return to enrolling institution for follow up imaging at least once

Exclusion criteria

• 1. life expectancy of ≤ 6 months

• 2. inability to provide blood samples based on the judgment of the treating provider